NASDAQ:BOLD Boundless Bio (BOLD) Stock Price, News & Analysis $1.41 +0.03 (+2.17%) As of 10:09 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Boundless Bio Stock (NASDAQ:BOLD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Boundless Bio alerts:Sign Up Key Stats Today's Range$1.40▼$1.4150-Day Range$1.08▼$1.6352-Week Range$0.96▼$1.68Volume1,407 shsAverage Volume178,064 shsMarket Capitalization$31.67 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. Read More Boundless Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreBOLD MarketRank™: Boundless Bio scored higher than 58% of companies evaluated by MarketBeat, and ranked 435th out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingBoundless Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialBoundless Bio has a consensus price target of $4.00, representing about 187.8% upside from its current price of $1.39.Amount of Analyst CoverageBoundless Bio has only been the subject of 1 research reports in the past 90 days.Read more about Boundless Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Boundless Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Boundless Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBoundless Bio has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Boundless Bio has been sold short.Short Interest Ratio / Days to CoverBoundless Bio has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Boundless Bio has recently decreased by 76.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBoundless Bio does not currently pay a dividend.Dividend GrowthBoundless Bio does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.51 News SentimentBoundless Bio has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Boundless Bio this week, compared to 1 article on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Boundless Bio insiders have not sold or bought any company stock.Percentage Held by Insiders23.10% of the stock of Boundless Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBoundless Bio has minimal institutional ownership at this time.Read more about Boundless Bio's insider trading history. Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Boundless Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOLD Stock News HeadlinesBoundless Bio Reports First Quarter 2026 Financial Results and Business HighlightsMay 8, 2026 | globenewswire.comBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual MeetingApril 17, 2026 | globenewswire.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.June 12 at 1:00 AM | Porter & Company (Ad)NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness StrategyApril 1, 2026 | globenewswire.comBoundless Bio (BOLD) price target increased by 33.33% to 4.08March 27, 2026 | msn.comBoundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026March 17, 2026 | globenewswire.comBoundless Bio, Inc.: Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMarch 9, 2026 | finanznachrichten.deBoundless Bio beats fourth quarter loss estimatesMarch 9, 2026 | investing.comSee More Headlines BOLD Stock Analysis - Frequently Asked Questions How have BOLD shares performed this year? Boundless Bio's stock was trading at $1.18 on January 1st, 2026. Since then, BOLD stock has increased by 17.8% and is now trading at $1.39. How were Boundless Bio's earnings last quarter? Boundless Bio, Inc. (NASDAQ:BOLD) issued its quarterly earnings data on Friday, May, 8th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.09. When did Boundless Bio IPO? Boundless Bio (BOLD) raised $100 million in an IPO on Thursday, March 28th 2024. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are Boundless Bio's major shareholders? Boundless Bio's top institutional shareholders include Renaissance Technologies LLC (1.78%). View institutional ownership trends. How do I buy shares of Boundless Bio? Shares of BOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Boundless Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Boundless Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings5/08/2026Today6/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry PHARMACEUTICAL PREPARATIONS Sub-IndustryN/A Current SymbolNASDAQ:BOLD CIK0001782303 Webwww.boundlessbio.com Phone(858) 766-9912FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Price Target for Boundless Bio$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+181.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-53.60% Return on Assets-34.66% Debt Debt-to-Equity Ratio0.52 Current Ratio9.87 Quick Ratio9.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book0.32Miscellaneous Outstanding Shares22,464,000Free Float17,275,000Market Cap$31.88 million OptionableNo Data Beta0.60 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BOLD) was last updated on 6/12/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredTHIS billionaire could hold your financial fate60-year Wall Street veteran Marc Chaikin is issuing an urgent warning about the billionaire behind an AI lab t...Chaikin Analytics | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump is positioned. Elon lights the fuse.A few days ago, while the market was bleeding, Trump posted on Truth Social, "The New Frontier of Finance is b...Crypto 101 Media | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent $181.39 billion on physical gold in Q1 2026 alone - and more than half of 2025's central b...Cedar Gold Group | SponsoredSMX Could Turn Proof Technology into Major Profit!SMX (Security Matters) PLC embeds invisible molecular markers into plastics, metals, fuels, and textiles, link...Smallcaps Daily | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredVWAV: Is This the Next Defense Breakout?VisionWave Holdings, Inc. (NASDAQ: VWAV) is developing a full-stack defense technology platform that integrate...Equiscreen | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boundless Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Boundless Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
